Henan Lingrui Pharmaceutical (SHA:600285) posted first-half attributable net profit of 495.1 million yuan, up 4.4% from 474.4 million yuan the previous year.
Earnings per share climbed to 0.871 yuan from 0.834 yuan, according to a half-year report filed on the Shanghai bourse.
Operating revenue climbed 2.3% year over year to 2.15 billion yuan from 2.10 billion yuan.
Shares of the pharmaceutical company fell 9% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.